LGHT vs. IDNA

Last updated Jul 15, 2026

LGHT (Langar Global HealthTech ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds. LGHT is actively managed, while IDNA is passively managed. Over the past year, LGHT returned -16.91% vs 59.85% for IDNA. A 0.59 correlation means they provide meaningful diversification when combined. LGHT charges 0.85%/yr vs 0.47%/yr for IDNA.

Performance

LGHT vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Langar Global HealthTech ETF (LGHT) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LGHT achieves a -14.31% return, which is significantly lower than IDNA's 27.00% return.

LGHT

• 1D: -2.51%
• 1M: 4.31%
• 6M: -16.76%
• YTD: -14.31%
• 1Y: -16.91%
• 3Y*: —
• 5Y*: —
• 10Y*: —

IDNA

• 1D: 0.91%
• 1M: 10.55%
• 6M: 16.50%
• YTD: 27.00%
• 1Y: 59.85%
• 3Y*: 12.94%
• 5Y*: -6.33%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

LGHT vs. IDNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024
LGHT Langar Global HealthTech ETF	-14.31%	-1.66%	0.23%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	27.00%	17.26%	-3.82%

Correlation

The correlation between LGHT and IDNA is 0.57, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.57
Correlation (All Time) Calculated using the full available price history since Jan 10, 2024	0.60

The correlation between LGHT and IDNA has been stable across timeframes, ranging from 0.57 to 0.59 - a consistent structural relationship.

LGHT vs. IDNA - Sectors Allocation Comparison

Sectors	LGHT	IDNA
Healthcare	98.0%	99.5%
Technology	0.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Industrials	-	0.3%
Real Estate	-	-
Utilities	-	-

Return for Risk

LGHT vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LGHT

LGHT Risk / Return Rank: 3
LGHT Sharpe Ratio Rank: 3
LGHT Sortino Ratio Rank: 3
LGHT Omega Ratio Rank: 3
LGHT Calmar Ratio Rank: 4
LGHT Martin Ratio Rank: 2

IDNA

IDNA Risk / Return Rank: 88
IDNA Sharpe Ratio Rank: 90
IDNA Sortino Ratio Rank: 89
IDNA Omega Ratio Rank: 80
IDNA Calmar Ratio Rank: 94
IDNA Martin Ratio Rank: 89

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LGHT vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Langar Global HealthTech ETF (LGHT) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	LGHT	IDNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.86	2.39	-3.25
Sortino ratio: Return per unit of downside risk	-1.11	3.27	-4.38
Omega ratio: Gain probability vs. loss probability	0.87	1.37	-0.50
Calmar ratio: Return relative to maximum drawdown	-0.66	5.64	-6.30
Martin ratio: Return relative to average drawdown	-1.32	15.56	-16.88

LGHT vs. IDNA - Sharpe Ratio Comparison

The current LGHT Sharpe Ratio is -0.86, which is lower than the IDNA Sharpe Ratio of 2.39. The chart below compares the historical Sharpe Ratios of LGHT and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

LGHT vs. IDNA - Drawdown Comparison

The maximum LGHT drawdown since its inception was -28.60%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for LGHT and IDNA.

Drawdown Indicators

	LGHT	IDNA	Difference
Max Drawdown Largest peak-to-trough decline	-28.60%	-68.26%	+39.66%
Max Drawdown (1Y) Largest decline over 1 year	-25.57%	-10.66%	-14.91%
Max Drawdown (3Y) Largest decline over 3 years	—	-29.46%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-68.26%	—
Current Drawdown Current decline from peak	-22.95%	-37.38%	+14.43%
Average Drawdown Average peak-to-trough decline	-8.26%	-36.28%	+28.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.85%	3.86%	+8.99%

Volatility

LGHT vs. IDNA - Volatility Comparison

Langar Global HealthTech ETF (LGHT) has a higher volatility of 7.75% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 6.88%. This indicates that LGHT's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LGHT	IDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.75%	6.88%	+0.87%
Volatility (6M) Calculated over the trailing 6-month period	15.73%	18.66%	-2.93%
Volatility (1Y) Calculated over the trailing 1-year period	19.79%	25.23%	-5.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	19.26%	28.51%	-9.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	19.26%	29.49%	-10.23%

LGHT vs. IDNA - Expense Ratio Comparison

LGHT has a 0.85% expense ratio, which is higher than IDNA's 0.47% expense ratio.

Dividends

LGHT vs. IDNA - Dividend Comparison

LGHT has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 0.85%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	0.85%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%
LGHT Langar Global HealthTech ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both LGHT and IDNA in my portfolio?

LGHT and IDNA have a correlation of 0.57, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LGHT or IDNA?

LGHT has higher volatility (7.75%) compared to IDNA (6.88%). In terms of maximum drawdown, LGHT dropped -28.60% vs IDNA's -68.26%.

Which ETF is better, LGHT or IDNA?

On 1-year performance, IDNA leads with 59.85% vs -16.91% for LGHT. On fees, IDNA is cheaper at 0.47% per year. On volatility, IDNA has been the lower-risk option at 6.88%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, LGHT or IDNA?

Over the 1-year period, IDNA has performed better with a 59.85% return vs -16.91%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, LGHT or IDNA?

IDNA is cheaper with a 0.47% expense ratio, compared with 0.85% for LGHT.

Which ETF pays a higher dividend yield, LGHT or IDNA?

IDNA has the higher dividend yield at 0.85%, compared with 0.00% for LGHT.

What is the main difference between LGHT and IDNA?

They also come from different issuers: Langar and iShares. Their fees differ too: 0.85% for LGHT and 0.47% for IDNA.

Which has better risk-adjusted returns?

IDNA currently has the higher Sharpe Ratio (2.39 vs -0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.